Swamy Tripurani, PhD
Swamy Tripurani joined the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in January 2023. He serves as a Program Director, managing a portfolio of small businesses that develop novel diagnostics, devices, and targeted therapeutics (Biologics and small molecules) for cancer detection, diagnosis, and treatment. He is also involved in the CARE (Connecting Awardees with Regulatory Experts) program, which fosters interactions between NCI-funded small businesses and the Food and Drug Administration (FDA).
Before joining NCI, Swamy worked at FDA for eight years as a research and regulatory review scientist. At FDA, he reviewed Chemistry Manufacturing and Controls (CMC) attributes in drug applications and non-clinical studies in tobacco product applications. He also developed and executed multiple research projects focused on understanding mechanisms behind adverse toxicities associated with FDA-approved cancer therapies, for which he received numerous honor awards. Swamy received his Ph.D. in Genetics and Developmental Biology from West Virginia University and completed his postdoctoral research training focused on reproductive disorders and cancer development at Baylor College of Medicine. He also worked as a clinical research associate in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center.